DSP-5336

Editas Medicine Advances Gene-Editing Therapy EDIT-401

Cambridge, Massachusetts – September 2, 2025 Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene-editing biotechnology company, has nominated EDIT-401,...

By cGxPwire Editor
November 4, 2025

Bio-Pharma

Sumitomo Pharma Unveils Promising Data in Blood Cancers

Marlborough, Massachusetts – November 3, 2025 Sumitomo Pharma America, Inc. (SMPA) announced compelling new investigational data from multiple clinical...